Malarone (Proguanil Hydrochloride, Atovaquone)

Malarone is an antimalarial medication indicated for the prevention and treatment of malaria caused by Plasmodium falciparum.

• Pre‑exposure prophylaxis: prevents malaria infection in travelers to endemic regions.
• Post‑exposure prophylaxis: reduces risk of malaria after possible mosquito exposure.
• Acute uncomplicated malaria: treats confirmed P. falciparum infection, including chloroquine‑resistant strains.

• Atovaquone blocks the mitochondrial electron transport chain of Plasmodium parasites, disrupting ATP synthesis, while proguanil is metabolised to cycloguanil, which inhibits the parasite's dihydrofolate reductase enzyme. The combined actions produce synergistic parasite killing and prevent replication of the malaria organism.

Malarone may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Abdominal pain: cramping or discomfort in the abdomen.
• Diarrhoea: loose stools, usually self‑limiting.
• Metallic taste: altered taste perception.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Severe hypersensitivity: including anaphylaxis or Stevens‑Johnson syndrome.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Haemolytic anaemia: especially in patients with G6PD deficiency.
• Severe neutropenia: marked reduction in white blood cells.
• Cardiac arrhythmia: rare QT‑interval prolongation.
• Visual disturbances: blurred vision or photophobia.

Before prescribing Malarone, clinicians should consider several safety factors.

• Pregnancy: safety not established; use only if potential benefit outweighs risk.
• Breastfeeding: unknown safety; weigh infant risk against maternal benefit.
• Renal impairment: dose adjustment may be required; monitor renal function.
• Drug resistance: ensure adherence to full regimen to minimise resistance development.
• Concomitant medications: review for potential interactions before initiation.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Malarone can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Rifampicin: markedly lowers plasma concentrations of both components.
• Protease inhibitors (e.g., ritonavir): may increase atovaquone levels, risking toxicity.
• Phenobarbital: induces metabolism, reducing drug exposure.

Moderate Interactions (Monitor Closely)

• Macrolide antibiotics (e.g., azithromycin): may increase QT‑interval prolongation risk.
• Sulfonamides: additive hypersensitivity potential.
• Warfarin: may potentiate anticoagulant effect, requiring INR monitoring.